Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
PRevention of End Stage Kidney Disease by Darbepoetin Alfa In Chronic Kidney Disease Patients With nondiabeTic Kidney Disease
- First Posted Date
- 2012-04-19
- Last Posted Date
- 2018-04-18
- Lead Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
- Target Recruit Count
- 476
- Registration Number
- NCT01581073
- Locations
- 🇯🇵
Showa University School of Medicine, Shinagawa, Tokyo, Japan
Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling
- Conditions
- Myocardial Infarction
- Interventions
- Drug: Control Saline
- First Posted Date
- 2012-02-24
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT01538771
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam, Korea, Republic of
A Pilot Clinical Study Evaluating the Effect of Parathyroid Hormone (PTH) Lowering On Erythropoietin Consumption in Calcitriol-Resistant Patients
- Conditions
- Moderate to Severe Secondary HyperparathyroidismStage 5 Chronic Kidney Diseases
- Interventions
- First Posted Date
- 2012-01-10
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 65
- Registration Number
- NCT01506947
A Clinical Study of KRN321 in Adult Subjects With Myelodysplastic Syndrome
- Conditions
- MDS
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2015-03-04
- Lead Sponsor
- Kyowa Kirin Co., Ltd.
- Target Recruit Count
- 45
- Registration Number
- NCT01497145
Darbe Administration in Newborns Undergoing Cooling for Encephalopathy
- Conditions
- Hypoxic Ischemic Encephalopathy
- Interventions
- Drug: Placebo
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 30
- Registration Number
- NCT01471015
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
🇺🇸Intermountain Medical Center, Sandy, Utah, United States
🇺🇸Vanderbilt University School of Medicine, Nashville, Tennessee, United States
Study to Evaluate Darbepoetin Alfa in Pediatric Subjects With Anemia Due to Chronic Kidney Disease
- First Posted Date
- 2011-09-02
- Last Posted Date
- 2016-06-17
- Lead Sponsor
- Amgen
- Registration Number
- NCT01428154
To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2012-07-19
- Lead Sponsor
- Green Cross Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT01363934
Darbepoetin Alfa in Patients With Anemic Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2011-05-30
- Last Posted Date
- 2017-12-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 147
- Registration Number
- NCT01362140
- Locations
- 🇨🇭
Research Site, Zurich, Switzerland
Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01222195
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Comparison Study of Standard Care Against Combination of Growth Factors Agents for Low-risk Myelodysplastic Syndromes
- Conditions
- Myelodysplastic Syndrome
- Interventions
- First Posted Date
- 2010-09-08
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Barts & The London NHS Trust
- Target Recruit Count
- 360
- Registration Number
- NCT01196715
- Locations
- 🇬🇧
Birmingham Cancer Research UK Clinical Trial Unit, Birmingham, United Kingdom
🇬🇧St Bartholomew's Hospital, London, United Kingdom
🇬🇧CECM Institute of Cancer, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.